Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.58 |
| ▸ | CCR8 | P51685 | 1/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 10/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3388222 | 0.90 | CCR1 (0.41) | CCR1CCR8METAP2HIF1A | |
| SCHEMBL4167622 | 0.85 | CCR1 (0.71) | CCR1CCR8CYP2A6METAP2TGFBR1 | |
| SCHEMBL3391256 | 0.76 | CCR1 (0.52) | CCR1CCR8CYP2A6METAP2TGFBR1 | |
| SCHEMBL196966 | 0.75 | CCR1 (1.00) | CCR1CCR8CYP2A6METAP2TGFBR1 | |
| SCHEMBL30511194 | 0.75 | CCR1 (1.00) | CCR1CCR8CYP2A6METAP2TGFBR1 | |
| SCHEMBL29388304 | 0.75 | CCR1 (1.00) | CCR1CCR8CYP2A6METAP2TGFBR1 | |
| SCHEMBL29751933 | 0.73 | CCR1 (0.94) | CCR1CCR8CYP2A6METAP2TGFBR1 | |
| SCHEMBL20557390 | 0.73 | CCR1 (0.94) | CCR1CCR8CYP2A6METAP2TGFBR1 | |
| SCHEMBL3423401 | 0.73 | CCR1 (0.94) | CCR1CCR8CYP2A6METAP2TGFBR1 | |
| SCHEMBL29751919 | 0.73 | CCR1 (0.94) | CCR1CCR8CYP2A6METAP2TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010514-B1 | 3-(PYRIDIN-2-YL)-[1,2,4]-TRIAZINES FOR USE AS FUNGICIDES | BASF SE (DE) | 2010-12-29 | — | — | EP | claimed |
| US-20090111692-A1 | 3-(Pyridin-2-Yl)-[1,2,4]-Triazines as Fungicides | BASF AKTIENGESELLSCHAFT (DE) | 2009-04-30 | — | — | US | claimed |
| EP-2010514-B1 | 3-(PYRIDIN-2-YL)-[1,2,4]-TRIAZINES FOR USE AS FUNGICIDES | BASF SE (DE) | 2010-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111692-A1 | 3-(Pyridin-2-Yl)-[1,2,4]-Triazines as Fungicides | CBR3, CBR1, TH | CCR1 131/4885CCR8 738/4885CYP2A6 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.